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Abstract.  A  family of genes related to the bcl-2 pro- 
tooncogene has recently emerged. One member of this 
family, mcl-1,  was cloned from a human myeloblastic 
leukemia cell line (ML-1) undergoing differentiation. 
The intracellular  localization of mcl-1,  as well as the 
kinetics of its expression during differentiation, have 
now been studied.  These studies show that the intra- 
cellular distribution of mcl-1  overlaps with, but is not 
identical to, that of bcl-2:mcl-1  is similar to bcl-2 in 
that the mcl-1  protein has a prominent mitochondrial 
localization,  and in that it associates with membranes 
through its carboxyl hydrophobic tail.  mcl-1  differs 
from bcl-2, however, in its relative distribution among 
other (nonmitochondrial/heavy  membrane) compart- 
ments,  mcl-1  also being abundant in the light mem- 
brane fraction of immature ML-1  cells while bcl-2 is 
abundant in the nuclear fraction.  Similarly,  in differen- 
tiating ML-1  cells, the timing of expression of mcl-1 
overlaps with, but is not identical to, that of bcl-2: the 
mcl-1  protein increases rapidly as cells initiate 
differentiation,  and mcl-1  is a labile protein.  In con- 
trast, bcl-2 decreases gradually as cells complete 
differentiation.  Overall, the mcl-1  and bcl-2 proteins 
have some properties in common and others that are 
distinct.  A burst of expression of mcl-1,  prominently 
associated with mitochondria,  complements the con- 
tinued expression of bcl-2 in ML-1  cells differentiating 
along the monocyte/macrophage pathway. 
M 
CL-1, a  member of the bcl-2 family, was cloned 
from the ML-1 human myeloblastic leukemia cell 
line (26).  ML-1 cells proliferate  as immature  my- 
eloblasts,  and they differentiate  to monocytes and macro- 
phages  upon  exposure  to  the  phorbol  ester,  12-0-tetra- 
decanoylphorbol 13-acetate  (TPA)  I (9). The progression to 
differentiated phenotype is accompanied by a loss of prolifer- 
ative capacity without substantial loss of viability, mcl-1 was 
isolated by screening  for genes that increase in expression 
early  in  the  switch  from  proliferative  to  differentiating 
phenotype (26). 
It  is  the  carboxyl portion  of mcl-1 that  has  sequence 
similarity  to bcl-2 (the carboxyl 139 out of the 350 amino 
acid residues of mcl-1 [25]; bcl-2 sequence [8, 52]).  At the 
extreme carboxyl terminus,  both mcl-1 and bcl-2 have a hy- 
drophobic stretch (19-20 amino acids);  in bcl-2, this stretch 
mediates  the association of the protein with membranes (6, 
7, 38, 51). bcl-2 was initially  reported to localize to mito- 
chondrial membranes and has since also been found in other 
intraceUular  membrane-containing  compartments,  includ- 
ing the nuclear envelope and endoplasmic  reticulum (21, 27, 
33).  Recent data show that bcl-2 associates with the outer 
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mitochondrial  membrane, and that it is targeted there by the 
hydrophobic  carboxyl terminus (27, 35, 38). 
Along with its remarkable intraceUular distribution,  bcl-2 
has an interesting  function,  which is to inhibit  cell death. 
This can be seen in cell lines dependent on growth factors, 
where exogenous introduction of bcl-2 inhibits the apoptosis 
produced by growth factor deprivation (16, 31, 39, 53). bcl-2 
can similarly  inhibit cell death caused by certain cytotoxic 
agents (23, 46, 48) or by apoptosis-inducing  gene products 
such as c-myc (3,  14). The role of bel-2 in inhibiting  death 
is also seen in vivo: in mice lacking bcl-2, the lymphoid sys- 
tem appears normal at birth, but subsequently  collapses be- 
cause of apoptosis of lymphoid cells (36, 54). Conversely, 
mice expressing a transgenic bcl-2 exhibit enhanced survival 
of lymphoid cells (31, 48, 49, 50).  Finally, the endogenous 
pattern of expression of bcl-2 reflects its role in the inhibition 
of apoptosis (22). For example, bcl-2 is not expressed in the 
majority of immature  thymocytes (CD4÷CD8+), which are 
susceptible to apoptotic death;  however, bcl-2 is expressed 
in those cells that survive and continue to differentiate  (17, 
29, 55). 
Like mcl-1, other genes in the bcl-2 family  exhibit  se- 
quence relatedness  in the carboxyl portion.  Cellular genes 
in this family include bcl-x (4), bax (40), A1 (28), and ced-9 
(20).  Although  the intraceUular  sites of action  of many of 
these gene products have not yet been fully elucidated,  it is 
known that most can influence cell death.  Some, like mcl-1 
and  bcl-2,  cause an  enhancement  of cell  viability  under 
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(e.g., bax; reference 40) cause an inhibition. Two viral genes 
(BHRF1  [41] and LMW5 [37]) arc distantly related to bcl-2. 
The BHRF1  gene product is membrane-associated,  and it 
has recently been reported to inhibit cell death and to local- 
ize  to  mitochondria  (19,  41).  One  aim  of  the  research 
reported in this paper was to investigate the intracellular  lo- 
calization and membrane association of one of the cellular 
members of the bcl-2 family, mcl-1. 
In contrast to the sequence relatedness in the carboxyl por- 
tion, mcl-1  differs from bcl-2 and other family members in 
its amino terminal portion. One difference is that the extreme 
amino terminus of mcl-1 has partial signal sequence charac- 
ter (26). Thus, as part of our studies on localization, we con- 
sidered whether mcl-1 might be processed by the endoplas- 
mic  rcticulum  through  a  signal  sequence-mediated  mech- 
anism. A second difference between mcl-1 and bcl-2 is that 
mcl-1  contains PEST sequences (26), which frequently sig- 
nal rapid protein turnover (43). We thus measured the half- 
life of mcl-1 with the expectation that mcl-1 might be a labile 
protein,  bcl-2 is a long-lived protein, having  a half-life of 
10-14 h (12, 24, 32).  We also monitored the expression of 
mcl-1  and bcl-2 during TPA- induced ML-1 cell differentia- 
tion;  this was to determine whether the patterns  of expres- 
sion of the two proteins were noncoordinate, as might be ex- 
pected with differing stabilities. 
In sum,  we have  examined the intracellular  localization 
and kinetics of expression of the mcl-1 protein. Our findings 
show that in ML-1  cells initiating  differentiation  along the 
monocyte/macrophage  pathway, continuous  expression  of 
bcl-2 is accompanied by a burst of expression of mcl-1, which 
is associated prominently with mitochondria. Overall, mcl-1 
and bcl- 2 exhibit overlapping, but nonidentical, intracellular 
distributions  and patterns  of expression. 
Materials and Methods 
Antibodies 
We produced polyclonal antiserum to the mcl-1 protein as follows: a eDNA 
containing the entire coding region of mcl-1 (plAfi [26])  was inserted into 
the pGEX-2T bacterial expression vector (Pharmacia Fine Chemicals, Pis- 
cataway,  NJ), using the EcoRI restriction site. This construct was intro- 
duced into a proteasc-ddicient (Ion-) strain of Escherichia coli, SRP84, 
and expression of the mcI-1-GST fusion protein was induced by addition of 
0.5 mM isopropyl-~-D-thio-galactopyranoside. After resuspension in MT- 
PBS buffer (150 mM NaCI,  16 mM Na2HPO4,  4 mM NaH2PO4,  pH 7.3), 
bacteria were lysed using a French pressure cell press (three times at 18,000 
psi). After centrifugation at 20,000 g, the mcl-bGST fusion protein in the 
supcrnatant was purified by affinity chromatography on ghtathione agarose 
(Sigma Immunochemicals, St. Louis, MO). On SDS-PAGE, the fusion pro- 
tein was seen as a doublet (66-68 kD). The mcl-1 portion of the fusion pro- 
tein could be released from the GST portion by cleavage with thrombin 
(Sigma). This yielded a band of 26.5  kD (the expected size for GST) and 
a doublet of  40-42 kD (approximately the expected size for mcl-1). The 42- 
kD component of this doublet was transferred to polyvinyldifluoride mem- 
brane and subjected to NH2-terminal sequencing using Edman degrada- 
tion. 15 amino acid residues were sequenced and found to be exactly as ex- 
pected: the first six residues derived from the polylinker, and the remaining 
nine were from the mcl-1 eDNA, with three of the latter deriving from 5' 
sequence  that is not normally translated (26). The 42-kD band was therefore 
excised and  used  for immunization of two New  Zealand white rabbits 
(JH746 and JH747). Immunizations were carried out by Hazelton Research 
Products Inc. (Denver, PA). 
The SPA825 and SPA827 antibodies were purchased from StressGen Bio- 
technologies  (Victoria,  B.C.,  Canada).  The  H5C6  antibody  to  CD63 
(Pltgp40,  see reference 1) was provided by Dr. James Hildreth (Johns Hop- 
kins  School  of  Medicine,  Baltimore,  MD). The  Abl(IA5  antibody  was  from 
Dr. Lanbo Chen (Dana-Farber  Cancer Institute,  Boston, MA). 
Affinity Purification and Analysis of the Specificity of 
the Anti-mcl-1 Antibody 
The ImmunoPure Ag/Ab immobilization kit (Pierce Chemical Co., Rock- 
ford, IL) was used for affinity purification, coupling of  the mcl-bGST fusion 
protein to the activated gel, and further steps, being carried out using the 
manufacturer's instructions. 
The specificity of the anti-mcl-1 antiserum was tested in Western blots 
against the bacterially produced mcl-bGST protein. SDS-PAGE was carried 
out using the mcl-bGST fusion protein (before and after digestion with 
thrombin to yield mcl-1 and GST). The anti-mcl-1 antiserum detected mcl-1 
before and after digestion of the fusion protein (Fig.  1 A, 66-68 kD fusion 
protein in lane 6and 40-42 kD mcl-1 protein in lane 5). The smaller bands 
detected may represent partial degradation products. The large band de- 
tected in lane 5 probably represents uncleared fusion protein. The antise- 
rum did not detect GST (Fig.  1 A, lane 4). Preimmune serum did not detect 
mcl-1  (Fig.  1.4,  lanes 1-3). 
Specificity was also tested in Western blots against lysates of ML-1 cells. 
Lysates from both uninduced (cont) and TPA- induced cells were used, since 
the latter would be expected to express higher levels of mci-1 (26). In cells 
induced with TPA for 3--4 h, the antiserum detected a doublet of 40-42 kD 
(Fig. 1 B, lane 8) that was not detected by preimmune serum (Fig.  1 B, lane 
10).  The affinity-purified antibody preparation also detected tiffs doublet 
(Fig. 1 B, lane 6). The appearance of this doublet was blocked by previous 
addition of a fivefold excess of mcl-I-GST fusion protein to the antibody 
(Fig. 1 B, lane 2), but it was not blocked by addition of the same concentra- 
tion of GST protein (Fig.  1 B, lane 4). These data show that our antibody 
preparations specifically detect mcl-1. This antibody does not exhibit cross- 
reactivity to bcl-2, which was detected as a single band of 26 kD (antibody 
from Dako Corp., Carpinteria, CA). The affinity-purified anti-mcl-I anti- 
body preparation was used in nil further experiments, with the exception 
of immunoprecipitations, where the anti-mcl-1 antiserum was used. With 
immunoprecipitation, as with Western blotting (Fig.  1 B),  the specific 
mcl-1 bands were well separated from nonspecific bands, as determined by 
using preimmune serum (see Figs. 4/1 and 8). 
Iramunofluorescence Microscopy 
Immunofluorescent staining of ML-I cells was carried out after 3  ×  104 
cells were cytocentrifuged onto coverslips. Cells were fixed in 2% parafor- 
maldehyde in PBS (15 rain), washed with PBS, and blocked and permeabi- 
lized in PBS containing 2% goat serum, 0.1% saponin, and 0.02%  NaN3 
(15 min). Cells were then incubated for 1 h with afffinity-purified mci-1 anti- 
body (5 ~g/ml in PBS containing 3 % BSA). After three washes with PBS, 
cells were incubated for 1 h with fluorescein- or Texas red-conjugated ggat 
anti-rabbit IgG antibody (10 ~g/ml; Jackson ImmunoResearch Laborato- 
ries,  Inc.,  West Grove,  PA).  After three washes with PBS,  cells were 
mounted and observed using conventional or confocal fluorescence micros- 
copy. All the above steps were carried out at room temperature. Sequential 
confocal images (from a "Z series") were superimposed  to produce a projec- 
tion image when a fluorescent image was compared to its phase-contrast 
counterpart. 
Two-color staining was carried out essentially as above, except for the 
addition of a second primary antibody. The secondary antibody to the sec- 
ond primary antibody was Texas red- or FITC-conjugated goat or sheep 
anti-mouse IgG antibody. Rbodaminel23 was purchased from Molecular 
Probes, Inc.  (Eugene, OR),  and it was applied to cells at  10 ~g/ml for 
30 rain. 
SubceUular Fractionation 
For differential centrifugation, cells (1-2  x  l0  s) were collected by cen- 
trifugation, washed once with PBS and twice with hypotonic buffer (10 mM 
Hepes, pH 7.4, 42 mM KCI, and 5 mM MgC12), rcsuspended in 2 rul of 
hypotonic buffer containing protease inhibitors (1  mM PMSF, 0.1  mM 
EDTA, 0.1 mM EGTA, 1 mM DTT, 1 izg/ml pepstatln A, 1 ~g/ml leupeptin, 
and 5 ~g/ml aprotinin), and lysed with a Dounce homogenizer. The total 
cell lysate (T) obtained was then centrifuged at 500 g for 5 rain. The peUet 
was washed three times with 1.6 M  sucrose and lysed in 0.5-1  ml Lysis 
buffer (50 mM Tris-Cl, pH 8.0, containing 1% NP-40,  0.1% SDS, 2 mM 
EDTA, and the above protease inhibitors), to yield the nuclear fraction (N). 
The supernatant was subjected to further centrifugation at 10,000 g for 30 
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fusion protein (Fusion,  lanes 2, 3, 5, and 6), or GST itself 0anes 
1 and 4) were produced by expression in Escherichia  coli.  These 
proteins were subjected to SDS-PAGE, with the mcl-I-GST fusion 
protein being used both before 0anes 3  and 6) and after (lanes 2 
and 5) cleavage with thrombin (which cleaves the GST away from 
the mcl-1).  Western blotting was  carried out using either preim- 
mune serum (lanes 1-3) or immune serum (bleed (2), lanes 4-6). 
(B) ML-1  cells were grown in the absence (cont) or presence of 
TPA (10  -9 M  for 3.75 h).  Western blotting was carried out using 
lysate from the equivalent of 4  x  106 cells in each lane.  Affinity- 
purified  anti-mcl-1  antibody  (lanes  1-6)  was  used  either alone 
(lanes 5 and 6) or after preincubation with a fivefold excess of mcl- 
1-GST fusion protein (Fusion,  lanes I  and 2) or GST (lanes 3 and 
4). The reel-1 antiserum was also used without purification (bleed 
(9), lanes 7and 8), along with preimmune serum from the same 
rabbit (lanes 9 and 10). Antiserum to bcl-2 is shown for compara- 
tive purposes (lanes//and  12).  Double arrows indicate the upper 
min. The resulting pellet was washed with 1 ml hypotonic buffer and lysed 
in lysis buffer to yield the heavy membrane fraction (H). The supernatant 
was subjected  to centrifugation at 150,000 g for 1 h, with the final pellet 
being suspended  in lysis buffer to yield the light membrane fraction (L), 
and the final supernatant yielding the eytosolic  fraction (C). 
To assess the membrane association of mcl-l, Triton X-114 fractionation 
and phase separation were carried out as described (5). 
Transfection of  racl-1 into cos-1 Cells 
mcl-1 cDNAs were inserted into the EcoRI site of an expression vector that 
uses the SV-40 early promoter (pSG5;  Cloning Systems;  Stratngene,  La 
Jolla, CA). One construct, pSG5-mcl-1, was constructed to contain the en- 
tire mcl-I coding region; this construct was derived by digesting plA6 (26) 
with EcoRl and iigating the released reel-l-containing fragment into pSG5. 
A second construct, pSG5-mcI-1AC27, was constructed to lack the hydro- 
phobic stretch at the carboxyl terminus, with the carboxyl  27 amino acids 
of mcl-I being replaced by a stuffer fragment, pSG5-mclqAC27 was derived 
as follows: first, a plasmid containing the mcl-I coding region (plambda5) 
was partially digested  with Eco0109 and DraII to remove a fragment that 
contains the carboxy127 amino acids (yielding plambda5AEcx~0109#5  [25], 
which contains nucleotide residues 33-1029 of the mcl-1 eDNA). The trun- 
cated mcl-1 from this plasmid was excised from Bluescript with EcoRI and 
BssHII, and it was cloned into pSG5 by blunt end ligation;  a stop codon 
present in pSG5 results in the formation of a protein that has the same mo- 
lecular weight as wild-type  reel-l, but that lacks a hydrophobic domain at 
its carboxyl terminus (amino acid residues 1-323 of mcl-I are followed by 
translated vector sequences,  yielding a protein that has the same molecular 
weight as mcl-1, but that migrates slightly more slowly (see reference 2 and 
references therein). Using the DEAE-dextran method (45), these plasmids 
were transfected into cos-1 cells that had been grown to 30-50% confluence. 
After 24 h, these cells were assayed for membrane association of the mci-1 
protein, as described above. 
Western Blotting 
Western blotting was  carried  out  using  standard  methods  with minor 
modifications (11). Briefly, cells were washed twice with ice-cold PBS, lysed 
by resuspcnsion in SDS sample buffer (62.5 mM Tris-Cl,  pH 6.8, 2% SDS, 
5 % 2-mercaptcethanol, 10  % glycerol, and 0.01% bromphenol blue), boiled 
for 5 rain, and stored at -20"C. Cell lysates were subjected to SDS-PAGE 
(12%) and transferred to nitrocellulose  membrane. The membranes were 
rinsed with PBS, blocked with 5 % nonfat dry milk in PBS, washed with 
PBS, incubated for 2 h with the mcl-I antibody (5/~g/mi [in PBS containing 
3% BSA and 0.02% NAN3]), and washed with PBS. Detection used either 
125I-protein A or horseradish pemxidase-conjugated  secondary antibodies 
(donkey anti-rabbit  Ig or sheep anti-mouse Ig [Amersham Corp., Arlington 
Heights,  IL] diluted at 1:1,000 in 2% horse or sheep serum), followed by 
incubation with enhanced chemiluminescence reagents. The above incuba- 
tions and washes were carried out at room temperature. 
Densitomea'ic scanning was used to estimate relative amounts of the 
mcl-I protein, using autoradiographs from several different exposure times 
and avoiding the use of overexposed autoradiographs.  In scans of Western 
blots (see Figs. 5 and 6), the values used represent the total mcl-I protein 
since the various forms of reel-1 were not separated well enough to be quan- 
titated individually. In Fig. 6, the fold increase in reel-1 at various times after 
addition of TPA was calculated  relative to the amount of reel-1 present at 
time 0. 
Metabolic Labeling and Immunoprecipitation 
Metabolic labeling and immunoprecipitation were carried out using estab- 
lished methods (11). Cells were washed twice and suspended at 2.5 ×  106 
cells/ml, using methionine-free RPMI medium 1640 containing 7.5% dia- 
lyzed serum. (When a time point of 24 h was used,  the medium consisted 
of this  methionine-depleted medium  [90%]  plus  standard  methionine- 
containing medium [10%]).  At various  times after addition of L-[35S]me  - 
thionine (0.2 mCi/ml), 5  ×  106 cells were  washed  twice with PBS and 
lysed in 50 mM Tris-C1, pH 7.6, containing 150 mM NaCI,  1% bovine he- 
moglobin, 1% NP-40, 0.5% deoxycholate,  0.1% SDS, 2 mM EDTA, 1 mM 
and middle mcl-1 protein bands apparent at early times (3-4 h) after 
exposure to TPA. 
Yang et al. mcl-1 Has a Prominent  Mitochondrial Localization  1175 Figure 2. Immunofluorescent  staining for the mcl-1 protein is prominent in punctate, cytoplasmic organelles that accumulate Rhodamine123. 
ML-1 cells were incubated  with TPA (as in Fig. 1) to induce expression  of the mcl-1 protein. (A and B) Immunofluorescent staining with 
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A,  1 mM iodoacetamide,  and"  0.0259[  NAN3. Lysates  were precleared 
using normal rabbit serum, followed by Staphylococcus aureus Cowan I 
(Boehringer Mannheim Biochemicais,  Indianapolis,  IN).  All steps were 
carried out at 4°C. The cleared lysates were incubated with antiserum (or 
preimmune serum) for 1 h, followed by protein A-Agarose for 1 h. After 
two washes with dilution buffer (50 mM Tris-Cl, pH 7.6, 150 mM NaC1, 
0.1% bovine hemoglobin, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 1 mM 
EDTA, and 0.025%  NAN3), one wash with TSA (10 mM "Iris, pH 8,  140 
mM NaCI, and 0.025% NAN3), and one washed with 50 mM Tris-Cl,  pH 
6.8, 2× SDS sample buffer was added, and the samples were boiled for 5 
min, centrifuged, and the superuatant was subjected to SDS-PAGE (15%). 
After electrophoresis,  the gel was fixed in 30% methanol/10%  acetic acid 
for 1 h, treated with ENHANCE (Du Pont Pharmaceuticals,  W'dmington, 
DE), dried, and exposed  to x-ray film. 
For pulse-chase metabolic labeling,  cells were incubated (pulse)  with 
L-[3~S]methionine for 3 h, as above.  They were then washed twice with 
methionine-free RPMI 1640 medium and resuspended (chase) at 3  ×  105 
cells/ml in RPMI 1640 medium containing three times the standard concen- 
tration of methionine. 
In Vitro Transcription and Translation 
A plasmid containing the mcl-1 coding sequence (p3.2;  reference 26) was 
linearized at the 3' end of the cDNA insert and used in in vitro transcription 
with T3 or T7 RNA polymerase.  Translation was carried out using a rabbit 
reticulocyte lysate system (Novagen, Inc., Madison, WI) in the presence or 
absence of canine pancreatic microsomai membranes (Promega Corp., 
Madison, WI), following the manufacturer's instructions. 
Results 
Prominent Mitochondrial Localization of the 
mcM Protein 
We  used  immunofluorescence,  with  the  afffinity-purified 
anti-mcl-1 antibody preparation, to assess the intracellular 
localization of mcl-1 in ML-1 cells. Upon exposure to TPA 
for 3-4 h, ML-1 cells express high levels of  mcl-1 mRNA and 
are  committing  to  differentiation,  but  they  do  not  yet 
manifest phenotypic maturation (25,  26).  They thus have 
only a scant cytoplasm, visible as a narrow rim surrounding 
the nucleus (10). We observed bright, punctate staining for 
mcl-1  in  the  cytoplasm  of these  cells  (Fig.  2  A).  The 
specificity of this staining was demonstrated by its inhibition 
upon addition of excess mcI-1-GST protein (Fig. 2 B), but 
not GST. Diffuse staining was also seen in the nucleus, but 
this was not as bright as the cytoplasmic staining, and it was 
not specifically inhibited by mcl-I-GST (Fig. 2, A and B). 
As compared to TPA-induced cells, much lower levels of 
mcl-1 were present in uninduced cells (data not shown), con- 
sistent with their lower levels of mcl-1 mRNA (26). 
To better visualize the localization of the mcl-1 protein, we 
viewed TPA-induced ML-1 cells by confocal microscopy. We 
found the specific staining for mcl-1 (Fig. 2 D) to colocalize 
with dark cytoplasmic organelles (Fig. 2 C). The mcl-1 pro- 
tein appeared to surround these organelles, resulting in a 
roughly spherical, often hollow, appearance (e.g., Fig. 2 D, 
above  the  label  C).  These  organelles  accumulated  the 
mitochondrial dye, Rhodamine123 (Fig. 2, E and F). 
To confirm the mitochondrial localization of mcl-1,  we 
used two-color staining using the above anti-mcl-1 antibody 
preparation along with antibodies known to stain mitochon- 
dria (AB10AS, or the SPA825 antibody to grp75 [30]).  The 
pattern of staining observed with the anti-mcl-1  antibody 
(Fig. 3, A and C) was essentially identical to that obtained 
with the mitochondria-specific antibodies (Fig. 3, B and D). 
In contrast, a dramatic difference was seen upon two-color 
staining with the antibody to mcl-1 and antibody to CD63 
(data not shown), which stains primarily lysosomes in my- 
eloid cells (1). A difference was also seen upon staining with 
anti-mcl-1 and an antibody that stains endoplasmic reticu- 
lum (SPA827 antibody to immunoglobulin heavy chain bind- 
ing protein [BiP];  reference 34), the latter yielding a fine, 
reticular pattern very different from the coarse granular pat- 
tern of mcl-1 (data not shown). As a whole, the experiments 
above demonstrated that mcl-1 was present in the cytoplasm, 
localizing prominently to mitochondria; they thus provided 
an initial parallel between the localization of mcl-1 and that 
of bel-2. 
Membrane Association of the mcl-1 Protein 
To test for membrane association of mcl-1, we used Triton 
X-114  extraction  and  phase  separation.  This  procedure 
separates integral membrane proteins from soluble proteins 
(5).  In ML-1 cells exposed to TPA for short times (3-4 h), 
we detected mcl-1 as a doublet (Fig. 4 A, bands of 42 and 
40 kD,  which are termed the upper and middle bands be- 
cause of the detection of an additional lower band at later 
time points [see below and Fig. 6]). mcl-1 was present in the 
phase containing the membrane proteins (Fig. 4 A, lane 8, 
memb.), but not in the phase containing the soluble proteins 
(Fig. 4 A, lane 6, aq). mcl-1 was detected using immune (Fig. 
4 A, lane 8), but not preimmune (Fig. 4 A, lane 7) serum. 
As expected, mcl-1  was detected at higher levels  in TPA- 
induced cells (Fig. 4 A, lane 8) as compared to uninduced 
cells (Fig. 4 A, lane 4).  These experiments demonstrated 
that mcl-1 is a  membrane-associated protein,  providing a 
further parallel to bel-2. 
We also studied the membrane association of mcl-1 upon 
transient transfection into cos-1 cells. We compared a vector 
containing wild-type mcl-1 (pSGSmcl-1) with a vector lack- 
ing a hydrophobic carboxyl terminus (pSGSmcI-1AC27). We 
found  the  wild-type  pSGSmcl-1  to  be  predominantly  a 
membrane-associated protein (90%; Fig. 4 B, lanes 7vs 8); 
the endogenous mcl-1 in cos-1 cells was also faintly detecta- 
ble in the membrane fraction (Fig. 4 B, lanes 1 and 3). In 
contrast, pSGSmcl-1 AC27 was predominantly in the aqueous 
fraction (96%; Fig. 4 B, lane 6). Thus, as in bcl-2 (7, 35, 
38), a hydrophobic domain at the carboxyl terminus appears 
important for the membrane association of mcl-1. 
the anti-mcl-I antibody. The antibody was preincubated with bacterially produced GST protein in A. (GST did not cause any change as 
compared to no-GST controls [not shown]). The antibody was blocked by preincubation with bacterially produced mcI-I-GST protein in 
B.  The arrow indicates the bright, punctate, cytoplasmic staining that represents mcl-l. (C and D) Confocal microscopy of the im- 
munofluorescent  staining for mcl-1, mcl-1 immunofluorescence  is in D and the corresponding phase contrast image is in C. The correspon- 
dence between mcl-I and dark cytoplasmic organelles is indicated by the letters at the periphery of the cell. (E and F) Accumulation  of 
the mitochondriai dye, Rhodamine123. Dye accumulation is in F,, and the corresponding phase contrast image is in E. The bars on the 
figures correspond to 10/~m. 
Yang et al. mcl-1  Has a Prominent  Mitochondrial  Localization  1177 Figure 3. Immunofluorescent  staining for mcl-1 colocalizes with mitochondrial markers.  ML-1 cells were exposed to TPA (as in Fig.  1, 
except that TPA was applied at 8.3 x  10  -1° M for 4 h). (A and B) Cells were stained using both the antibody to mcl-I (A) and the SPA825 
antibody to mitochondrial grp75 (B). Detection of mcl-1 was with FITC-conjugated  goat anti-rabbit  IgG and that of grp75 was with Texas 
red-conjugated goat anti-mouse  IgG. Arrows point out regions of correspondence on a representative cell. A small fraction of TPA-induced 
ML-1 cells undergo cell death instead of differentiation (9); these cells (d) contained lower levels of mcl-1 than the majority of the differen- 
tiating cell population. (C and D) Cells were stained using both the antibody to mcl-1 (C) and the Abl0A5 antibody that recognizes mito- 
chondria (D). The methods used were similar  to those in A and B, except that visualization  was by confocal rather than conventional  micros- 
copy. Bar,  l0 #m. 
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tions upon fractionation of ML-1 cells  by differential  centrifuga- 
tion. ML-1 cells were incubated  in the absence (Control) or pres- 
ence  of TPA  (10  -9  M  for  4  h),  and  they  were  subjected  to 
differential ¢entrifugation.  An aliquot (100 t~g protein) of each frac- 
tion, or of the total initial cell lysate (T), was assayed for the pres- 
ence of mcl-1, bcl-2,  and the grp75 mitochondrial protein using 
Western blotting.  The fractions are labeled as follows: N, nuclear; 
H, heavy membrane; L, light membrane; C, cytosolic. Recovery 
of protein in the combined fractions (N+H+L+C) was 80-100%. 
Of the protein recovered,  8-12% was in N, ,o19%  in H,  1%21% 
in L, and "052% in C, with little  difference between Control and 
TPA-induced  ceils.  Cell equivalents  loaded per lane (xl06) were 
1.1, 15.7, 7.0, 6.4, 2.6,  1.1, 16.7, 9.3,  10.7, and 3.5 for lanes  1-10, 
respectively. The percentage of  mcl-1 recovered in the N, H, L, and 
C fractions from untreated (Control) ceils was estimated to be 3 %, 
54%, 30%, and 13%, respectively. The mcl-1 in the cytosolic frac- 
tion (C) is thought to represent  protein released  into this fraction 
during  homogenization since  some  grp75  was  also  found there 
(lanes 5 and 10). The percentage of bcl-2 recovered  in the N, H, 
and L fractions from untreated (Control) cells was estimated to be 
44%,  55%, and 1%, respectively. 
Figure 4. The mcl-1 protein associates with membranes through the 
hydrophobic carboxyl terminus.  (,4) ML-1 ceils were incubated  in 
the absence (lanes 1-4) or presence (lanes 5-8) of TPA (as in Fig. 
1, except that TPA was applied  at  1.7  x  10  -9 M).  Soluble  (aq.) 
and  membrane  (memb.)  proteins  were  separated  using  Triton 
X-114. Aliquots of each phase were subjected to immunoprecipita- 
tion using either  preimmune  serum  (pre.)  or anti-mcl-I  serum 
Differential Distribution of the mcl-1 and bcl-2 
Proteins upon SubceUular Fractionation 
We were unable to find satisfactory conditions for staining 
simultaneously for mcl-1 and bcl-2, although we were able 
to carry out simultaneous  immunofluorescent  staining  for 
mcl-1  and various mitochondrial markers  (Fig.  3).  There- 
fore,  we fractionated ML-1 cells and monitored mcl-1  and 
bcl-2 by Western blotting, When immature ML-1 cells were 
fractionated by differential  centrifugation,  mcl-1  and bcl-2 
were both present in the heavy membrane fraction (Fig.  5, 
Control,  lane  3),  which  contained  most  of  the  grp75 
(SPA825) mitochondrial marker. This accorded with the mi- 
tochondrial staining seen upon immunofluorescence micros- 
copy (Figs. 2 and 3). mclq, like bcl-2, was present in other 
(Ab.). Arrows indicate  the upper and middle mcl-1 protein bands. 
The  doublet  of lower  molecular  mass  ('035-36  kD,  lane  8) 
represents  a small amount of degradation of mcl-1 that can occur 
during the Triton X-114  procedure. (B) Cos-1 cells were transfected 
with pSG5-mclq or pSG5mcl-lAC27,  which does not contain a hy- 
drophobic stretch at the carboxyl terminus.  Parallel  cultures  were 
not transfected (Cont., lanes I and 2), or they were transfected with 
pSG5 vector alone (no insert, lanes 3 and 4). The membrane as- 
sociation of mcl-1 was assessed  as in A, except that detection was 
by Western blot instead of immunoprecipitation,  pSG5mcI-IAC27 
was constructed to have the same molecular weight as the wild-type 
protein, although it proved to migrate slightly more slowly on poly- 
acrylamide  gel  electrophoresis  (see  reference  2  and  references 
therein). 
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ever, mcl-1 differed from bcl-2 in relative distribution among 
these fractions. For example, in addition to both being in the 
heavy  membrane  fraction  in  immature  cells,  mcl-1  was 
prominent in  the  light membrane  fraction (30%  of total 
mcl-1;  Fig.  5, lane 4),  where bcl-2 was barely detectable, 
while bcl-2 was prominent in the nuclear fraction (44 % of 
total bcl-2 similar to previous reports [27]; Fig. 5, lane 2) 
where mcl-1  was  barely detectable.  The nuclear  fraction 
from differential centrifugation can contain contaminating 
mitochondria (47); this is unlikely to account for the abun- 
dance of bcl-2 there since this fraction did not contain grp75 
(Fig. 5, lane 2). Similarly, the light membrane fraction can 
contain some small mitochondria (47); this is unlikely to ac- 
count for the abundance of mcl-1  there, since this fraction 
was also devoid of grp75  (Fig. 5, lane 4).  The light mem- 
brane fraction can additionally contain disrupted mitochon- 
drial outer membranes (47); this is unlikely to account for 
the abundance of mcl-1 relative to bcl-2 there (Fig. 5, lane 
4) since bcl-2 is an outer membrane protein (27, 35, 38). The 
light membrane fraction also contains endoplasmic reticu- 
lure, Golgi, lysosomes, peroxisomes, ribosomes, and frag- 
ments of plasma membrane (47); thus, further work will be 
necessary to determine which of these components contain 
mcl-1. 
When TPA-induced ML-1 cells were subjected to differen- 
tial centrifugation, mcl-1 protein was present in all fractions 
(Fig. 5, T/A, lanes 7-10). When homogenizing TPA-induced 
cells for differential centfifugation, we were unable to cleanly 
lyse all cells without causing some nuclear damage (assessed 
by microscopic inspection).  Thus,  the  results  from TPA- 
induced cells demonstrated a general increase in mcl-1, but 
they could not be used to calculate specific changes in the 
different fractions. The prominent visualization of mcl-1  in 
association with mitochondria (Figs. 2 and 3), together with 
its presence in additional fractions besides the mitochondria- 
enriched heavy membrane fraction (Fig. 5), suggest that lo- 
cal mcl-1 concentrations may be higher at the mitochondrial 
site than elsewhere. Similarly, bcl-2 was first localized to mi- 
tochondria (21) and was later shown, by high resolution tech- 
niques, to also be present elsewhere (27). 
Increased Expression  of  mcl-I and Continued 
Expression of  bcl-2 during ML-I Cell Differentiation 
We followed the time course of expression of the mcl-1 pro- 
tein during ML-1 cell differentiation. Total mcl-1 protein lev- 
els increased within 3-6 h of exposure to TPA approximately 
seven- to nine-fold, respectively; Fig. 6, lanes 3 and 4) after 
the increase in mcl-1  mRNA at 1-3 h (26); a decline from 
this early peak was seen at 24-72 h, although mcl-1  levels 
remained above baseline (see 72-h time point, Fig. 6, lane 
7). At this time, bcl-2 levels had decreased (by ~40% on a 
per-cell basis, as in other similar differentiating systems [1 I, 
21]). We have found the increase in mcl-1 expression to occur 
with a more consistent time course than the subsequent de- 
cline. Thus, mcl-1 more closely approached baseline levels 
at 72 h in some experiments (not shown) than in others (Fig. 
6; see also Figs.  1 and 2 in reference 26 for the timing of the 
decline in the mRNA). 
Several closely spaced bands represent the mcl-1 protein. 
For example, as shown above (Figs.  1, 4, and 5), mcl-1 ap- 
pears as a doublet in Western blots of cells exposed to TPA 
Figure 6. The mcl-1 and bcl-2 proteins exhibit distinct but overlap- 
ping profiles of expression during TPA-induced  ML-1 cell differen- 
tiation. ML-I cells were exposed to 5 x  10  -l° M TPA for the indi- 
cated times and  assayed for the presence  of mcl-1 or bcl-2 by 
Western blot.  Since a  small  mount  of cell  loss  accompanies 
differentiation, the number of viable cell equivalents loaded per 
lane decreased with time; these values (x  106)  were 2.1 at 0-3 h, 
1.8-1.9 at 6-24 h, and 1.7 at 48-72 h. The fold increase in total 
mcl-1, on a per-cell basis, was ,~1, 7, 9, 6, 6, and 4 at 1, 3, 6, 24, 
48, and 72 h, respectively. The amount of bcl-2 per cell remained 
constant until day 3, when a 40% decrease was noted.  At time 
points of'~ 24-72 h, a lower mcl-1 protein band was distinct in addi- 
tion to the upper and middle mcl-1 bands. As cells differentiated 
in response to TPA, the amount of protein (rag) per 106 cells in- 
creased from 0.12 at 0-3 h, to 0.15 at 6 h, 0.2 at 24 h, 0.26 at 48 h, 
and 0.32 at 72 h. 
for short times (3--4 h; Fig. 6, lane 3 upper and 24 h middle 
mcl-I bands). In Western blots of untreated cells, the upper 
band is less prominent (Fig. 6, lane 1). In cells exposed to 
TPA for longer times (e.g.,  Fig.  6,  lane 5),  an additional 
lower mcl-1 band becomes evident. This lower band is dis- 
tinct at 24 h (a very faint band may be seen at earlier times, 
Fig. 6, lane 4), and it becomes more intense at 48 and 72 h 
(Fig. 6, lanes 6 and  7). We are currently investigating the 
differences among the various mcl-1  bands.  The slow time 
course of appearance of the lower mcl-1  band suggests that 
enzymes responsible for the production of this form of mcl-1 
could be present at low levels in untreated cells, and could 
be induced at part of the differentiation program. Overall, 
ML-1 cell differentiation was accompanied by an increase in 
the mcl-1 protein, followed by a shift from abundance of the 
upper  and  middle  mcl-1  bands  to  the  middle  and  lower 
bands. This change in expression of  mcl-1 was superimposed 
upon continued, albeit declining, expression of bcl-2. 
Lability of  the mcl-I Protein and Lack of  Processing 
through a Signal Sequence-mediated Mechanism 
Because the amino terminus of mcl-1 has some characteris- 
tics of a  signal sequence (26), we tested for processing of 
mcl-1 through a signal sequence-mediated mechanism. We 
first translated  mcl-1  mRNA  in  vitro in  the  presence of 
microsomal membranes; the mcl-1 protein did not undergo 
cleavage (Fig. 7, lanes 6 and 7). We then tested the protease 
sensitivity of  the products of the in vitro translation reaction; 
the mcl-1 protein was not protected from protease digestion 
(Fig. 7, lanes 8 and 9 vs lanes 6 and 7), showing that mcl-1 
did not undergo translocation across the membranes.  This 
lack of cleavage of the protein and lack of translocation/pro- 
tease  protection  indicate  that  mcl-1  is  not  processed  by 
microsomal membranes through a signal sequence-mediated 
mechanism. 
We also used metabolic labeling/immunoprecipitation to 
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quence  mediated-mechanism.  Messenger  mRNA  representing 
mcl-1 (lanes 6--9) or B-lactamase (lanes 2- 5) was used in in vitro 
translation in the presence (lanes 3, 5, 7, and 9) or absence (lanes 
2, 4, 6, and 8) of  pancreatic microsomal membranes. After transla- 
tion, aliquots of each sample were exposed to trypsin (lanes 4, 5, 
8,  and  9).  When  B-lactamase was translated  in the presence  of 
membranes, the signal sequence present in the primary translation 
product  was cleaved,  yielding  a  shorter  form:  The longer  form 
predominated in the absence of membranes  (lane 2, long arrow), 
while the shorter form predominated in their presence (lane 3, short 
arrow). This shorter  form was protected  from trypsin  digestion, 
while the longer form was not (the short form does not disappear 
in lane 5 [compared to lane 3], while the long form does). A small 
amount of/$-lactamase remained undigested in lane 4. The size of 
the reel-1 in vitro translation product was ,040 kD. In the presence 
of membranes, the yield of mcl-1 was decreased slightly (lane 7). 
assess the kinetics of synthesis and degradation of the mcl-1 
protein in ML-1 cells. We found synthesis of the mcl-1 pro- 
tein to increase within 2  h  of exposure to TPA (,'o2.5-fold 
increase in [3~]methionine  incorporation into the upper and 
middle mcl-1 bands; Fig. 8 A, lane 7vs lane 2). Incorpora- 
tion into the upper band appeared to occur more rapidly than 
incorporation into the middle band.  We did not detect ap- 
preciable levels of the lower mcl-1 band at early time points 
(1-3 h; Fig.  8 A, lanes 6-8) upon immunoprecipitation, in 
agreement with results from Western blotting (Fig. 6, lanes 
2 and 3). The lower band was detectable upon pulse labeling 
for  24  h  (data  not  shown),  which  also  agreed  with  the 
findings from Western blots (Fig. 6, lane 5). We did not de- 
tect secretion of mcl-1 protein into the medium (Fig.  8 A, 
lane  5  and  10),  consistent  with  the  lack  of  processing 
through a  signal sequence-mediated mechanism (Fig.  7). 
Using pulse-chase, we found turnover of the mcl-1 protein 
to occur rapidly in both uninduced  and TPA-induced cells 
(Fig. 8 B, lanes 2-5 and 8-11, respectively). Just as incorpo- 
ration into the upper band occurred more rapidly (Fig. 8 A), 
turnover of this band appeared to be somewhat more rapid 
(Fig.  8 B, half-life of disappearance of "01 h  for the upper 
band, and 2-3 h for the middle band). While a rapid decrease 
in intensity was seen for both of these bands, an increase was 
seen in the relative intensity of the middle band as compared 
to the upper band (Fig. 8 B, lanes 8-10). The more rapid ini- 
tial appearance of the upper band (Fig.  8 A), as well as its 
Figure 8. The mcl-1 protein can be rapidly synthesized and rapidly 
turned  over. (A) ML-1 ceils  were exposed to [35S]methionine in 
the absence (lanes 1-5) or presence 0aries 6-10) of 1.7  x  10  --9 M 
TPA. Immunoprecipitation of cell (C) lysates for reel-1 was carried 
out at 1, 2, and 3 h (5  x  l0  s ceils). The culture medium (M) was 
assayed at 3 h.  Immunoprecipitatiun  using preimmune  serum (p; 
lanes 4 and 9) served as a control. Arrows indicate the upper and 
middle mcl-I protein bands. (B) Cells were subjected to a 3-h pulse 
exposure  to  [35S]methionine as  in A,  followed by a  chase  with 
medium  containing  excess nonradioactive  methionine.  Immuno- 
precipitation was carried out at 0, 1, 3, 6, and 9 h into the chase. 
As in A, preimmune  (p; lanes 1 and 7) was used as a control. 
rapid disappearance along with the relative increase in the 
middle band (Fig. 8 B), suggested that the upper band could 
be a  precursor of the middle band;  thus,  the middle band 
could represent a processed form of mcl-1, the upper band 
being chased by conversion to the middle band. At 3 h into 
the chase,  the upper and middle mcl-1 bands were clearly 
Yang et al. mcl-I Has a  Prominent Mitochondrial Localization  1181 discernible, although the lower mcl-1 band was not (Fig. 8 
B, lane 10); this is probably related to the fact that the la- 
beled mcl-1 protein disappears rapidly and to the fact that the 
lower mcl-1 band is only faintly discernible at this time point 
on Western blots (Fig. 6, lane 4). At time points after 3 h 
of  the chase, the mcl-1 protein had declined to essentially un- 
detectable levels. 
Interestingly,  we  detected  a  protein  of low  molecular 
weight that coimmunoprecipitated with mcl-1 (22-kD band 
in Fig. 8 A, lane 7 and 8 and B, lane 8). In a side-by-side 
coimmunoprecipitation, the 22-kD band that coimmunopre- 
cipitated with mcl-1 was identical is size to a band that coim- 
munoprecipitated with bcl-2 (data not shown, see references 
15 and 40 regarding proteins of  this size that immunoprecipi- 
tate with bcl-2). We are therefore investigating whether this 
mcl-l-associated protein might be bax (40),  which is of the 
appropriate size and which has recently been shown to inter- 
act with mcl-1 in the yeast two-hybrid system (44). We did 
not observe coimmunoprecipitation between mcl-1 and bcl-2 
(bcl-2  migrated more slowly than the 22-kD protein, bcl-2 
having an apparent molecular mass of 25-26 kD). Overall, 
these experiments demonstrate that mcl-1 can be synthesized 
rapidly and degraded rapidly, and that mcl-1 coimmunopre- 
cipitates with a 22-kD protein as does bcl-2. The increase 
in steady-state levels of mcl-1 seen during the early stages 
of TPA-induced differentiation (Fig. 6) appears to relate to 
enhanced synthesis of the protein rather than to inhibition of 
its degradation (Fig. 8). 
Discussion 
The members of the bcl-2 gene family appear to function in 
the control of cell viability. For example, bcl-2, mcl-1, bcl-x, 
and ced9 can enhance viability under conditions that would 
otherwise produce cell death (3, 4,  14,  16, 20, 21, 23, 39, 
42, 53). The question thus arises as to the rationale for the 
existence of multiple gene products with apparently similar 
functions. One possibility is that different members of this 
family might act within different intracellular sites. Different 
family members might also act within different cell types or 
within one cell type at different stages of differentiation. Ac- 
cordingly, different  family members might be expected to ex- 
hibit nonoverlapping patterns of inter- or intracellular distri- 
bution.  We have investigated the intracellular localization 
and pattern of expression of one of the cellular members of 
the bcl-2 family, mcl-1. In differentiating ML-1 cells, we find 
that the distribution and expression of mcl-1 and bcl-2 over- 
lap, but that they are nonidentical. Thus, the expression of 
these two bcl-2 family members with similar function may 
relate, at least partially, to the differential intracellular distri- 
bution of the encoded proteins and to the differential timing 
of their expression during ML-1 cell differentiation. 
mcl-1, like bcl-2, exhibits a prominent mitoehondrial lo- 
calization upon  visualization by  immunofluorescence mi- 
croscopy.  Furthermore, mcl-1 associates with membranes 
through its hydrophobic carboxyl tail, as does bcl-2 (38). 
However, the distribution of mcl-1, as assessed by differential 
centrifugation, reveals some differences from bcl-2: in addi- 
tion to both being in the heavy membrane fraction in imma- 
ture ML-1  cells, mcl-1 is also abundant in the light mem- 
brane fraction, and bcl-2  is also abundant in the nuclear 
fraction. The biological function underlying the coexpres- 
sion of these two bcl-2 family members may relate to this 
overlapping but nonidentical pattern of intracellular subcom- 
partmentalization. This is because different members of the 
bcl-2 family can interact. For example, bcl-2 interacts with 
several  proteins,  including bax (15, 40),  and we have ob- 
served mcl-1 to coimmunoprecipitate with a protein of simi- 
lar size. Such interactions can have a dramatic effect on func- 
tion. In the case of bcl-2 and bax, heterodimers promote cell 
viability in contrast to bax/bax homodimers which have the 
opposite effect (56). The intracellular compartmentalization 
and interactions of all of the various cellular bcl-2 family 
members have not yet been fully explored in mammalian sys- 
tems. Indeed, the breadth of the intracellular distribution of 
bcl-2 has been appreciated only recently (27, 33). If overlap- 
ping but nonidentical distributions prove to be a common 
finding, intracellular subcompartmentalization could be an 
important determinant of the interactions, and thus the net 
effects, of the members of this family. 
In addition to overlapping intracellular distributions, the 
mcl-1 and bcl-2 proteins exhibit overlapping expression dur- 
ing TPA-induced ML-1 cell differentiation, mcl-1 expression 
is at a minimum in immature ceils, and it increases rapidly 
in early differentiation. In contrast, bcl-2 expression is at a 
maximum in immature cells, and it declines slowly in con- 
cert with the completion of the maturation process.  Thus, 
throughout most of differentiation, dramatically increased 
expression of mcl-1 is superimposed upon continued expres- 
sion of bcl-2. Both of these gene products have the capacity 
to inhibit apoptosis, bcl-2 having been tested in a host of 
different cell lines, including differentiating systems (13, 16, 
18, 29, 39, 50, 53), and mcl-1 having recently been tested in 
a  defined system in which apoptosis is induced by c-myc 
(42). Future experiments will examine whether coexpression 
of mcl-1 and bcl-2 might allow additive or complementary 
effects.  For example, might the increase in mcl-1 in ML-1 
cells serve to augment the effects of bcl-2 during the critical 
period of differentiation-induction?  Thus, while bcl-2 (along 
with minimum amounts of mcl-1) might suffice for the main- 
tenance of viability during continuous proliferative cycling, 
the transition to differentiation  might constitute an additional 
stress on the mechanisms that maintain cell viability, requir- 
ing the supplemental expression of mcl-1. A role for mcl-1 
in such critical cell transitions or acute stress would be well 
served by the fact that mcl-1 is a labile PEST protein that can 
be synthesized and degraded rapidly. 
In ML-1 cells, expression of  both mcl-1 and bcl-2 declines, 
but it does not disappear, as differentiation approaches com- 
pletion.  Maximal levels  of these viability-promoting gene 
products may no longer be necessary when cells reach the 
fully differentiated, viable, nonproliferative stage. This would 
be consistent with the hypothesis that increased expression 
of mcl-1  is  of primary importance when cell viability is 
threatened,  such  as  under  conditions of susceptibility to 
apoptosis, or when cell fate is being determined, such as 
during the decision to exit the proliferation cycle and initiate 
differentiation. 
Note added in proof. As this article was being reviewed, bcl-x was reported 
to also localize to mitochondria (Gonztlez-Garcia,  M., R. Ptrez-Balles- 
tero, L. Ding, L. Duan, L. H. Boise, C. B. Thompson, andG. Nufiez. 1994. 
bcl-xL is the major bcl-x mRNA form expressed during murine develop- 
ment and its product localizes to the mitochondria. Development (Cam&). 
120:3033. 
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